Randomized double-blind controlled study of different antiemetic drugs in gynecological day surgery with remimazolam and alfentanil

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100053316

Enrollment

Unknown

Registered

2021-11-18

Start date

2021-11-15

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative nausea and vomiting (PONV)

Interventions

DT group:Dexamethasone and Tropisetron

DDgroup:Dexamethasone and Droperidol

DC group:Dexamethasone

Eligibility

Sex/Gender

Female

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Gynecological patients who are scheduled to undergo hysteroscopy under total intravenous anesthesia; 2. ASA I-II grade; 3. Aged 18-65 years.

Exclusion criteria

Exclusion criteria: 1. During pregnancy and lactation; 2. History of chronic pain, sedatives and analgesics; 3. Patients with allergies to any study drug; 4. Obese patients; 5. The operation time is more than 1 hour; 6. Patients discharged the next day; 7. Patients with missing follow-up.

Design outcomes

Primary

Measure	Time frame
The incidence of PONV;	—

Secondary

Measure	Time frame
Severity of postoperative nausea and vomiting;The time the patient left the hospital after the operation;Overall patient satisfaction;Remimazolam and Alfentanil consumption;Anesthesia time;	—

Countries

China

Contacts

Public ContactJi Fanceng

Weifang People's Hospital

jifanceng@163.com+86 13563698838

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026